PUBLIC COMPANY
saveRona Therapeutics Inc
updated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engagerRoche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional milestones.biospace · 23d ago
- Roche returns to Hansoh with broad $15B ADC dealRoche is offering $400 million upfront and over $15 billion in biobucks to team up with Hansoh Pharmaceutical in hopes of developing a portfolio of new antibody-drug conjugates using the latter’s i…biospace · 27d ago
- Roche extends China deal streak with $1B pact for RNAi obesity drugAn alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on medicines that can lower levels of “visceral” fat.biopharma_dive · 1mo ago
- Roche expands obesity R&D footprint with Rona deal worth $1B+Roche has gained access to a genetic obesity approach from China's Rona Therapeutics for up to $100 million in upfront and near-term payments.biospace · 1mo ago
- Roche's seventh China deal this year is a $1.2B obesity pact with Rona TherapeuticsRoche is set to fork over up to $100 million in upfront and near-term milestone payments to license an asset in a red-hot field for obesity: ALK7 inhibition. The deal with RNA interference speciali…endpoints · 1mo ago
- Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity raceRoche has committed $100 million in upfront and near-term payments to license Rona Therapeutics’ ALK7 drug candidate, joining Alnylam, Arrowhead, GSK and Novo Nordisk in an emerging obesity niche.fiercebiotech · 1mo ago
comments(0)
5-min edit window · permanent after that